Nebivolol Ipca (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic antagonist used primarily in cardiovascular disease management.

• Hypertension: lowers systolic and diastolic blood pressure, reducing risk of stroke and myocardial infarction.
• Heart failure: improves left‑ventricular ejection fraction and symptoms in patients with reduced ejection fraction.
• Elderly patients with hypertension: provides effective blood‑pressure control with a favorable metabolic profile.

• Nebivolol Hydrochloride selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric oxide synthase, leading to nitric‑oxide‑mediated vasodilation, which further contributes to blood‑pressure reduction without significant β2‑receptor blockade.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially after the first dose.
• Fatigue or tiredness during dose titration.
• Nausea or mild gastrointestinal upset.
• Bradycardia: heart rate below 60 bpm in some patients.
• Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia or sinus arrest requiring medical attention.
• Atrioventricular block or other high‑grade heart‑block events.
• Bronchospasm in patients with asthma or chronic obstructive pulmonary disease.
• Allergic reactions such as rash, pruritus, or angio‑edema.
• Hepatic dysfunction manifested by elevated transaminases.
• Acute heart‑failure decompensation in susceptible individuals.

Before initiating therapy, clinicians should evaluate cardiovascular status and comorbid conditions.

• Blood pressure monitoring: check regularly during dose titration.
• Cardiac function assessment: perform ECG and echocardiography in patients with known heart disease.
• Asthma or COPD caution: avoid in patients with active bronchospasm.
• Concomitant beta‑blockers: avoid duplicate therapy unless specifically indicated.
• Renal or hepatic impairment: consider dose adjustment and close monitoring.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can alter the pharmacodynamics of several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other beta‑blockers: additive negative chronotropic effects may cause severe bradycardia.
• Calcium‑channel blockers (verapamil, diltiazem): increase nebivolol plasma concentrations, raising risk of heart block.
• Clonidine: abrupt discontinuation may precipitate rebound hypertension.
• Insulin or oral hypoglycemics: nebivolol may mask hypoglycaemic symptoms.
• MAO inhibitors: potential for hypertensive crisis when combined.

Moderate Interactions (Monitor Closely)

• NSAIDs: may reduce antihypertensive efficacy.
• Diuretics: monitor electrolytes and blood pressure.
• Antidepressants (SSRIs, SNRIs): observe for additive blood‑pressure effects.
• Anti‑arrhythmic agents (e.g., amiodarone): watch for QT‑interval changes.
• Lipid‑lowering agents (statins): monitor for altered metabolism.